Basilea and Phare Bio Partner to Develop AI-Designed Broad-Spectrum Antibiotic
核心洞察
Basilea Pharmaceutica and Phare Bio (搜索) announced a strategic partnership to develop a novel broad-spectrum antibiotic using AI-driven drug discovery to address critical unmet needs for patients with life-threatening infections.
Phare Bio (搜索) will deploy its generative AI platform to design molecules meeting pre-defined target product profiles, while Basilea assumes responsibility for subsequent development and clinical advancement.
The collaboration represents a new model for antibiotic innovation, combining cutting-edge AI technology with industrial expertise to address antimicrobial resistance (搜索) and economic sustainability challenges.
Basilea Pharmaceutica Ltd and Phare Bio (搜索) Inc. announced a strategic partnership on December 11, 2025, to jointly develop a novel broad-spectrum antibiotic using artificial intelligence-driven drug discovery. The collaboration aims to address critical unmet medical needs for patients battling life-threatening infections caused by high-priority gram-negative pathogens (搜索).
AI-Driven Discovery Platform
Under the partnership agreement, Phare Bio (搜索) will deploy its generative AI platform to design molecules with antibacterial properties that meet a pre-defined target product profile (TPP). The platform is uniquely parameterized with drug-like properties and considers both unmet medical needs and features relevant for potential commercial success of a future product.
Following identification of molecules matching the specified profile, Basilea will assume responsibility for subsequent development activities, while Phare Bio (搜索) will be eligible to receive pre-defined success-based payments. This structure represents what the companies describe as a new model for antibiotic innovation, bridging technological advances in drug discovery with industrial expertise and economic sustainability.
Industry Leadership Perspectives
Dr. Akhila Kosaraju, president and CEO of Phare Bio (搜索), characterized the partnership as "a watershed moment for the field of antimicrobial resistance (搜索)." She emphasized that this marks the first time their cutting-edge AI drug discovery platform has been aligned with a partner committed to developing innovative drugs to address the need for novel antibiotics.
"It validates Phare Bio (搜索)'s hybrid model of nonprofit innovation and private-sector partnership as a viable route to solving one of the greatest public health crises of our time," Kosaraju stated.
Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, expressed enthusiasm about working with Phare Bio (搜索)'s innovative platform on antibiotic discovery. He noted that the partnership reflects a shared commitment to address the urgent need for novel antibiotics by advancing drug candidates with innovative features such as a novel mode of action.
Basilea CEO David Veitch added that partnering with Phare Bio (搜索) reflects the company's commitment to innovation in antibiotic discovery and development, noting that their AI platform could unlock transformative solutions for accelerated development of novel antibacterial treatments.
Company Backgrounds
Phare Bio (搜索), founded in 2020, is a biotech social venture that combines cutting-edge machine learning with world-class science to accelerate the discovery of urgently needed antibiotics. The company is backed by The Audacious Project, Google.org, ARPA-H, and other investors.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. The company has successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections (搜索) and Zevtera for the treatment of bacterial infections (搜索). Basilea maintains preclinical and clinical anti-infective assets in its portfolio and is listed on the SIX Swiss Exchange.